Skip to content

Study · Randomized controlled trial · n = 6 · 2005

6 results

Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.

Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Amber V, Patel S, Ghatei MA, Bloom SR

The Journal of clinical endocrinology and metabolism20 Sept 2005Cited by 472 (Europe PMC)

PMID16174713 (opens in a new tab)DOI10.1210/jc.2005-1468 (opens in a new tab)PepBankPUB-16174713
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In male volunteers, a 90-min kisspeptin‑54 infusion raised plasma LH more than a saline infusion.

    In plain wordsIn six male volunteers, kisspeptin‑54 raised LH levels more than saline did.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma LH
    Study

    n = 6

    Comparator
    Saline infusion
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Mean 90-min LH
    10.8 U/liter
    kisspeptin-54
    Mean 90-min LH
    4.2 U/liter
    saline

    Source sentences

    Summary
    Kisspeptin-54 infusion significantly increased plasma LH, FSH, and testosterone concentrations compared with saline infusion
    4 context sentences
    Summary · context
    mean 90-min LH: kisspeptin, 10.8 +/- 1.5 vs. saline, 4.2 +/- 0.5 U/liter
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In male volunteers, a 90-min kisspeptin‑54 infusion raised plasma FSH more than a saline infusion.

    In plain wordsIn six male volunteers, kisspeptin‑54 raised FSH levels more than saline did.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma FSH
    Study

    n = 6

    Comparator
    Saline infusion
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Mean 90-min FSH
    3.9 U/liter
    kisspeptin-54
    Mean 90-min FSH
    3.2 U/liter
    saline

    Source sentences

    Summary
    Kisspeptin-54 infusion significantly increased plasma LH, FSH, and testosterone concentrations compared with saline infusion
    4 context sentences
    Summary · context
    mean 90-min FSH: kisspeptin, 3.9 +/- 0.7 vs. saline, 3.2 +/- 0.6 U/liter
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In male volunteers, a 90-min kisspeptin‑54 infusion raised plasma testosterone more than a saline infusion.

    In plain wordsIn six male volunteers, kisspeptin‑54 raised testosterone levels more than saline did.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    IncreasePlasma testosterone
    Study

    n = 6

    Comparator
    Saline infusion
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Mean 180-min testosterone
    24.9 nmol/liter
    kisspeptin-54
    Mean 180-min testosterone
    21.7 nmol/liter
    saline

    Source sentences

    Summary
    Kisspeptin-54 infusion significantly increased plasma LH, FSH, and testosterone concentrations compared with saline infusion
    4 context sentences
    Summary · context
    mean 180-min testosterone: kisspeptin, 24.9 +/- 1.7 vs. saline, 21.7 +/- 2.2 nmol/liter
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In male volunteers, the plasma half-life of kisspeptin‑54 was calculated to be 27.6 min.

    In plain wordsIn six male volunteers, kisspeptin‑54 had a plasma half-life of about 27.6 minutes.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicablePlasma half-life
    Study

    n = 6

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Plasma half-life
    27.6 min
    kisspeptin-54

    Source sentences

    Summary
    The plasma half-life of kisspeptin-54 was calculated to be 27.6 +/- 1.1 min.
    3 context sentences
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In male volunteers, the mean metabolic clearance rate of kisspeptin‑54 was 3.2 ml/kg x min.

    In plain wordsIn six male volunteers, the body cleared kisspeptin‑54 at a mean rate of 3.2 ml/kg per minute.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableMetabolic clearance rate
    Study

    n = 6

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Mean metabolic clearance rate
    3.2 ml/kg x min
    kisspeptin-54

    Source sentences

    Summary
    The mean metabolic clearance rate was 3.2 +/- 0.2 ml/kg x min, and the volume of distribution was 128.9 +/- 12.5 ml/kg.
    3 context sentences
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.
  6. 06HumanRandomized controlled trialPharmacokinetics

    In male volunteers, the volume of distribution of kisspeptin‑54 was 128.9 ml/kg.

    In plain wordsIn six male volunteers, kisspeptin‑54 had a volume of distribution of 128.9 ml/kg.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    Not applicableVolume of distribution
    Study

    n = 6

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4 pmol/kg x min · intravenous infusion · 90 minAs given in this study (human).

    Measurements

    Volume of distribution
    128.9 ml/kg
    kisspeptin-54

    Source sentences

    Summary
    The mean metabolic clearance rate was 3.2 +/- 0.2 ml/kg x min, and the volume of distribution was 128.9 +/- 12.5 ml/kg.
    3 context sentences
    Summary · context
    This was a double-blind, placebo-controlled, crossover study.
    Summary · context
    Male volunteers (n = 6) were recruited.
    Summary · context
    Each volunteer received a 90-min i.v. infusion of kisspeptin-54 (4 pmol/kg x min) and a control infusion of saline (0.9%) in random order.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03315325

Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men

Quaid-e-Azam Universityn = 158 Aug 2014 to 5 Mar 2015

Sterility, Reproductive

Trial pageClinicalTrials.govUpdated 23 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.